# Treatment options for non-Hodgkin lymphoma
The treatment of non-Hodgkin lymphoma varies greatly depending on type, stage, and individual circumstances. Below is an overview of the main treatment approaches per category. Many patients receive combinations of these methods.
Chemotherapy
Chemotherapy usually consists of different substances given simultaneously or in sequence. The most well-known combination for aggressive forms (such as diffuse large B-cell lymphoma) is CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone. For less aggressive lymphomas, other combinations are sometimes used.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Chemotherapy works by damaging rapidly dividing cells (including cancer cells). Side effects may include: nausea and vomiting, hair loss, fatigue, increased risk of infection due to lower white blood cell counts, and bleeding due to lower platelets. These side effects are usually known in advance and are managed. Some chemotherapy drugs may have longer-term effects on the heart or fertility; this is always discussed beforehand.
Rituximab and rituximab-like agents
Rituximab is an antibody that targets CD20, a protein on B cells. It is widely used, both together with chemotherapy and alone. Similar agents are obinutuzumab and ofatumumab.
ProveniIncluded in official guidelines, or approved by EMA or FDA
These agents help the immune system better recognize and destroy tumor cells. They can be given as infusion (intravenous) or injection. Common side effects are reactions around the infusion (fever, chills, shortness of breath), especially with the first administration. The immune system may be temporarily weakened, which can cause infections. In rare cases, serious reactivation of certain viruses (such as hepatitis B) can occur.
Bispecific antibodies (checkpoint inhibitors of the bispecific type)
Epcoritamab and similar agents link tumor cells to the patient's own T cells, enabling the body to better deploy its own immune cells.
ProveniIncluded in official guidelines, or approved by EMA or FDA
(in relapsed/refractory disease)
These agents help the body's T lymphocytes attack cancer cells. Side effects may include: cytokine release syndrome (fever, chills, shortness of breath, blood pressure drop), neurotoxicity, and infections. These side effects can be serious and are closely monitored, especially at the beginning of treatment.
CAR-T-cell therapy
This is an advanced form of immunotherapy in which T cells from the patient are genetically modified in the laboratory so they can better recognize tumor cells. They are multiplied and returned to the patient.
ProveniIncluded in official guidelines, or approved by EMA or FDA
(in relapsed/refractory disease)
CAR-T cells multiply in the body and attack tumor cells. Common side effects are cytokine release syndrome (similar to severe flu: fever, shaking, shortness of breath, very low blood pressure) and neurotoxicity (confusion, seizures, loss of consciousness in severe cases). These can be severe at first but usually diminish. Existing immune cells (healthy B cells) can also be damaged, which may require antibody supplementation. CAR-T therapy requires hospitalization and intensive monitoring.
BTK inhibitors
Bruton tyrosine kinase inhibitors (ibrutinib, acalabrutinib, zandelisib) block a protein that B lymphocytes need to survive.
ProveniIncluded in official guidelines, or approved by EMA or FDA
(especially in certain types such as lymphocytic lymphoma)
These pills inhibit tumor growth by blocking signaling pathways in cancer cells. Side effects may include: diarrhea, fatigue, infections, bleeding (including minor bleeding from nose or gums), and heart rhythm disorders. Some patients also develop blood clots. The dose and duration depend on response and tolerability.
Venetoclax and BCL2 inhibitors
Venetoclax blocks a protein (BCL2) that helps cancer cells survive.
ProveniIncluded in official guidelines, or approved by EMA or FDA
(in combination with other agents)
These agents force tumor cells into programmed cell death. Side effects can include: diarrhea, infections (especially early in treatment, when tumor cell breakdown products are released), fatigue, and low blood cell counts. Tumor lysis syndrome (acute disruption from rapid cell death) can occur and requires preparation and monitoring.
Bendamustine
Bendamustine is a chemotherapy-like substance with both classical and immune mechanisms of action.
ProveniIncluded in official guidelines, or approved by EMA or FDA
This agent damages DNA in cells and activates immune cells. Side effects are comparable to those of classical chemotherapy: nausea, fatigue, low blood cell counts, increased infection risk. Sometimes skin reactions occur at the infusion site.
Radiation
For certain forms and stages, radiation therapy is sometimes given, especially targeting isolated lymph nodes or bulky disease.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Radiation damages cancer cells locally. Local side effects are possible (skin irritation, fatigue, mucositis if the throat or esophagus is involved). In the long term, there is a risk of secondary tumors and heart problems if large areas of the chest or abdomen are irradiated.
HDV and SVD regimens (dose-intensive chemotherapy with stem cell transplantation)
For certain types and relapses, intensive chemotherapy is given, with reinfusion of the patient's own or donor stem cells.
ProveniIncluded in official guidelines, or approved by EMA or FDA
(in selected patients)
This approach attempts to achieve maximal tumor control. Side effects are substantial: very low blood counts (requiring transfusion and with infection risk), mucositis, diarrhea, and severe fatigue. With allogeneic transplantation (donor stem cells), graft-versus-host disease occurs: the donor immune system attacks the recipient's body. This can last months to years and affect skin, digestive system, and lungs.
Immune checkpoint inhibitors (PD-1/PD-L1 blockers)
Nivolumab, pembrolizumab, and other agents block inhibitory signals so the immune system better attacks tumors.
ResearchediPositive results in clinical studies, not yet standard treatment
To **Established** (depending on type and context)
These agents help the body activate its own defense cells. Side effects arise because the immune system can become overactive: inflammation in lungs, liver, kidneys, bowel, thyroid, or brain can occur. Skin reactions, fatigue, and joint pain have also been reported. These side effects can be serious but often respond to steroids or treatment pause.
Brentuximab vedotin
This is a conjugated antibody (antibody-drug conjugate) that targets CD30.
ProveniIncluded in official guidelines, or approved by EMA or FDA
(in CD30-positive types)
The agent contains both a recognition engine (antibody) and a toxin that destroys tumor cells. Side effects include peripheral neuropathy (tingling, weakness in hands and feet), fatigue, infections, and skin reactions. Neuropathy can sometimes be long-lasting.
Lenalidomide and immunomodulators
Lenalidomide stimulates the immune system and disrupts tumor growth.
ProveniIncluded in official guidelines, or approved by EMA or FDA
(in certain types, sometimes in combination)
This agent increases T-cell activation and reduces blood vessel formation around tumors. Side effects can include: fatigue, constipation, neuropathy, increased infection risk, and risk of blood clots. Pregnancy is impossible (teratogenic).
Experimental approaches and investigational drugs
Various new agents are under investigation, including:
- Multi-antigen CAR-T cells (targeting multiple targets simultaneously)
- NK cell therapy (natural killer cells from donor, possibly from umbilical cord blood)
- New BTK and BCL2 inhibitors
- Combinations of immune checkpoint inhibitors
ExperimentaliOngoing in study setting, outcome still unknown
These medicines are still in clinical trials. Patients can enroll in trials if standard treatment is not helping or has been exhausted. The advantage is potential new efficacy; the disadvantage is uncertainty about side effects.
Supportive care
Beyond tumor-directed treatment, much support is important:
- **Infection prophylaxis**: antibiotics, antivirals, or antifungals to prevent infections
- **Transfusions**: red blood cells, platelets for severe deficiencies
- **Growth factors**: agents to stimulate white blood cell production
- **Anti-nausea medication**: medicines against nausea
- **Pain management**: pain relievers, sometimes stronger medications
- **Psychosocial support**: counseling, social work, sometimes antidepressants
These forms of care are part of every treatment plan.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._